Publications by authors named "Edward Libby"

Claim this Profile
I
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials.
Andrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, Gabriel O Cole, Blythe D Sather, Edward N Libby

Transplant Cell Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia.
Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Edward Libby

Blood Adv· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha, Edward N Libby

Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study.
Meletios A Dimopoulos, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Edward Libby

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, Efstathios Kastritis, Heather J Landau, Edward N Libby

Blood· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Î
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial.
Andrew J Cowan, Margot J Pont, Blythe D Sather, Cameron J Turtle, Brian G Till, Edward N Libby

Lancet Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and molecular response predictors of oral ixazomib and short-course rituximab in untreated iNHL.
Solomon A Graf, Ryan C Lynch, Chaitra S Ujjani, Ted A Gooley, Heather Rasmussen, Edward N Libby

Blood Adv· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiographic Response of Solitary Plasmacytomas After Conformal Radiotherapy May Be Delayed: Outcomes in the 3D Era.
Samuel Kosydar, Avanti Gulhane, Edward Libby, Andrew J Cowan, Mary Kwok

Am J Clin Oncol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma.
Franck Morschhauser, Loretta Nastoupil, Pierre Feugier, Jean-Marc Schiano de Colella, Hervé Tilly, Edward N Libby

J Clin Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
Paul G Richardson, Susanna J Jacobus, Edie A Weller, Hani Hassoun, Sagar Lonial, Edward N Libby

N Engl J Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study.
Vaishali Sanchorawala, Giovanni Palladini, Monique C Minnema, Arnaud Jaccard, Hans C Lee, Edward Libby

Am J Hematol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Throughput Drug Screening and Multi-Omic Analysis to Guide Individualized Treatment for Multiple Myeloma.
David G Coffey, Andrew J Cowan, Bret DeGraaff, Timothy J Martins, Niall Curley, Edward N Libby

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and Management of Multiple Myeloma: A Review.
Andrew J Cowan, Damian J Green, Mary Kwok, Sarah Lee, David G Coffey, Edward N Libby

JAMA· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged Lenalidomide Therapy Does Not Impact Autologous Peripheral Blood Stem Cell Mobilization and Collection in Multiple Myeloma Patients: A Single-Center Retrospective Analysis.
Andrew J Cowan, Philip A Stevenson, Damian J Green, Sherilyn Tuazon, Edward N Libby

Transplant Cell Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Ryan C Lynch, Ryan D Cassaday, Stephen D Smith, Jonathan R Fromm, Andrew J Cowan, Edward N Libby

Lancet Haematol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Efstathios Kastritis, Giovanni Palladini, Monique C Minnema, Ashutosh D Wechalekar, Arnaud Jaccard, Edward Libby

N Engl J Med· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
Ajai Chari, Markus Munder, Katja Weisel, Matthew Jenner, Ceri Bygrave, Edward Libby

Adv Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study.
Andrew J Cowan, Helen Baldomero, Yoshiko Atsuta, Joseph Mikhael, Mahmoud Aljurf, Edward N Libby

Biol Blood Marrow Transplant· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Left Ventricular, Right Ventricular, and Left Atrial Strain in Light-Chain Amyloidosis.
Douglas J Leedy, Alexi Vasbinder, Hans D Huang, Robin Fernandes, Andrew J Cowan, Edward N Libby

JACC CardioOncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Constantine S Tam, Stephen Opat, Shirley D'Sa, Wojciech Jurczak, Hui-Peng Lee, Edward Libby

Blood· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.
Jorge J Castillo, Edward N Libby, Stephen M Ansell, M Lia Palomba, Kirsten Meid

Blood Adv· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy.
Mary-Elizabeth M Percival, Ryan C Lynch, Anna B Halpern, Mazyar Shadman, Ryan D Cassaday, Edward N Libby

JCO Oncol Pract· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation.
Andrew J Cowan, Damian J Green, Mehdi Karami, Pamela S Becker, Sherilyn Tuazon, Edward N Libby

Clin Lymphoma Myeloma Leuk· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma.
Edward Libby, Josh Epworth

J Adv Pract Oncol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Sagar Lonial, Hans C Lee, Ashraf Badros, Suzanne Trudel, Ajay K Nooka, Edward Libby

Lancet Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis